I be reby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

August 15, 2003

Date

Jessica Helmerson

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

: Klaus Giese et al.

Application No.

: 10/601,091

Filed

: June 19, 2003

For

: METASTATIC BREAST AND COLON CANCER REGULATED

GENES

Docket No.

: 59516-274/PP-01451

Date

: August 15, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO/SB/08 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted, Klaus Giese et al. DAVIS WRIGHT TREMAINE LLP

Jane E. R. Potter

Registration No. 33,332

Enclosure:

Postcard Form PTO/SB/08 Cited References (3)

2600 Century Square 1501 Fourth Avenue Seattle, WA 98101-1688 Phone: (206) 628-3150 Facsimile: (206) 628-7699 PTO/SB/08A (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Compr t if Known		
Application Number	10/601,091	
Filing Date	June 19, 2003	
First Named Inventor	Klaus Giese	
Art Unit		
Examiner Name		
Attornov Docket Number	50516-274/DD-01451	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-		11.0		
		US-				
		US-				
		US-				
		US-			1	
		US-				
		US-				
		US-				
		US-				

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T⁵
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	
		EP0848062A2	06-17-98			<u> </u>
	 		-			
	 					<u> </u>

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information. Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08B (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ork Reduction Act of 1995,no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sypsitute (1949/PTO				Complet if Known		
INFORMATION DISCLOSURE				Application Number	10/601,091	
STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	June 19, 2003	
				First Named Inventor	Klaus Giese	
			ecessary)	Art Unit		
				Examiner Name		
Sheet	2	of	2	Attorney Docket Number	59516-274/PP-01451	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
		DUFFY, Proteases as Prognostic Markers in Cancer, CLINICAL CANCER RESEARCH, 2:613-618, 1996.			
		CHEN ET AL., Membrane Proteases as Potential Diagnostic and Therapeutic Targets for Breast Malignancy, BREAST CANCER RESEARCH AND TREATMENT, 31:217-226, 1994.			

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0 031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

AND 1 9 THE RES

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

	information unless it displays a valid OMB control number.
Application Number	10/601,091
Filing Date	June 19, 2003
First Named Inventor	Klaus Giese
Group Art Unit	
Examiner Name	
Attorney Docket No.	59516-274/PP-01451

ENCLOSURES (check all that apply)						
Fee Transmittal Form Fee Attached Amendment/Response After Final Affidavits/declaratio Extension of Time Requ Express Abandonment Request Information Disclosure Statement; Form PTO/S Cited References (3) Certified Copy of Priority Document(s) Response to Missing Pa under 37 C.F.R. 1.52 or Response to Missing Parts/Incomplete Applica	Drawing(s) Request for Corrected Filing Receipt Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Declaration Statement under 37 CFR 3.73(b) Terminal Disclaimer Small Entity Statement Request for Refund	CD(s), Number of CD(s) After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Receipt Postcard Additional Enclosure(s) (please identify below):				
SIGN	ATURE OF APPLICANT, ATTORNEY,	OR AGENT				
Individual Name Jane E.	R. Potter	27476				
Signature	e Ellott					
Date August 15, 2003						
CERTIFICATE OF FACSIMILE TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date specified below.						
Typed or printed name Jessica Helmerson						
Signature	NOSSICA-HEIMERSON	Date: August 15, 2003				

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an a pplication. C onfidentiality is g overned by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.